Lupus (SLE) trials in Brazil

In Brazil 23 Also abroad 354

23 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Belo Horizonte, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Barretos, Belo Horizonte, Curitiba, Niterói, Rio de Janeiro, Salvador, São Paulo, Vitória
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Where
Belo Horizonte, Recife, Salvador, Santo André, Vitória
Age
18 years to 100 years
People
348 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00
Phase 1Taking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Porto Alegre, Ribeirão Preto, Sao Jose Rio Preto
Age
18 years to 75 years
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Barretos, Belo Horizonte, CuiabÃ¡, Fortaleza, Salvador
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Brasília, Campinas, São Paulo
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Campinas, Petrópolis, Salvado, Salvador, São Paulo
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Goiânia, Juiz de Fora, Porto Alegre, Ribeirão Preto, Salvador, São José do Rio Preto, São Paulo, Vitória
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Porto Alegre, São Paulo
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 2Taking people
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Where
Salvador
Age
12 years to 65 years
People
35 worldwide
Run by
Autolus Limited
See details and how to joinNCT07053800 · EU 2024-519941-32-00
Phase 1/2Not yet taking people in Brazil
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
Where
Ribeirão Preto, São Paulo
Age
18 years to 50 years
People
16
Run by
University of Sao Paulo
See details and how to joinNCT07659704
Phase 1Taking people
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Where
Porto Alegre, Salvador, São Paulo
Age
18 years to 65 years
People
48 worldwide
Run by
AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00
Phase 2Taking people
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Where
Curitiba, Juiz de Fora, Porto Alegre, Salvador, São José do Rio Preto, São Paulo, Valinhos
Age
18 years to 74 years
People
405 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00
Phase 2Taking people
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Brasília, Cuiab, Niterói, Porto Alegre, Ribeiro Preto, Salvador, São Paulo
Age
18 years and over
People
30 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07598396 · EU 2024-519930-22-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Belo Horizonte, Brasília, Curitiba, Fortaleza, Juiz de Fora, Porto Alegre, Salvador, Santo Ângelo, São Bernardo do Campo, Sao Jose Rio Preto, São Paulo, Valinhos, Vitória
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Where
São Paulo
Age
16 years and over
People
30 worldwide
Run by
Akebia Therapeutics
See details and how to joinNCT06419205
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Belo Horizonte, Porto Alegre, Ribeirão Preto, São Paulo
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 3Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Where
Porto Alegre, Salvador
Age
18 years to 75 years
People
680 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00
Phase 4Taking people
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Where
São Paulo
Age
12 years to 59 years
People
477
Run by
University of Sao Paulo General Hospital
See details and how to joinNCT07087912
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Campinas, São Paulo
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 1Taking people
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Where
Juiz de Fora, Porto Alegre, Salvador
Age
18 years to 65 years
People
142 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06576271 · EU 2024-514186-18-00
No phaseNot yet taking people in Brazil
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis
Where
São Luís
Age
18 years and over
People
100
Run by
Federal University of Maranhao
See details and how to joinNCT07493655